The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Targeting the TGFβ pathway for cancer therapy
Open accessAbstract
The TGFβ signaling pathway has pleiotropic functions regulating cell growth, differentiation, apoptosis, motility and invasion, extracellular matrix production, angiogenesis, and immune response. TGFβ signaling deregulation is frequent in tumors and has crucial roles in tumor initiation, development and metastasis. TGFβ signaling inhibition is an emerging strategy for cancer therapy. The role of the TGFβ pathway as a tumor-promoter or suppressor at the cancer cell level is still a matter of debate, due to its differential effects at the early and late stages of carcinogenesis. In contrast, at the microenvironment level, the TGFβ pathway contributes to generate a favorable microenvironment for tumor growth and metastasis throughout all the steps of carcinogenesis. Then, targeting the TGFβ pathway in cancer may be considered primarily as a microenvironment-targeted strategy. In this review, we focus on the TGFβ pathway as a target for cancer therapy. In the first part, we provide a comprehensive overview of the roles played by this pathway and its deregulation in cancer, at the cancer cell and microenvironment levels. We go on to describe the preclinical and clinical results of pharmacological strategies to target the TGFβ pathway, with a highlight on the effects on tumor microenvironment. We then explore the perspectives to optimize TGFβ inhibition therapy in different tumor settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101
Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability
Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., et al. (1995) · Science · doi:10.1126/science.7761852 · Cited by 2,270
TGFβ: the molecular Jekyll and Hyde of cancer
Bierie, B., & Moses, H. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1926 · Cited by 1,267
TGFβ signalling: a complex web in cancer progression
Ikushima, H., & Miyazono, K. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2853 · Cited by 1,173
Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation
Calon, A., Espinet, E., Palomo-Ponce, S., Tauriello, D. V. F., Iglesias, M., Céspedes, M. V., Sevillano, M., Nadal, C., Jung, P., Zhang, X. H.-F., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.013 · Cited by 1,060
TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression
Yang, L., Pang, Y., & Moses, H. L. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.04.002 · Cited by 1,023
Padua, D., & Massagué, J. (2009) · Cell Research · doi:10.1038/cr.2008.316 · Cited by 809
Extracellular control of TGFβ signalling in vascular development and disease
ten Dijke, P., & Arthur, H. M. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2262 · Cited by 778
TGF-β in progression of liver disease
Dooley, S., & ten Dijke, P. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1246-y · Cited by 718
Inflammation and EMT: an alliance towards organ fibrosis and cancer progression
López‐Novoa, J. M., & Nieto, M. A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900043 · Cited by 654
Intestinal Tumorigenesis in Compound Mutant Mice of both Dpc4(Smad4) and Apc Genes
Takaku, K., Oshima, M., Miyoshi, H., Matsui, M., Seldin, M. F., & Taketo, M. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81132-0 · Cited by 609
Desmoplastic Reaction in Pancreatic Cancer: Role of Pancreatic Stellate Cells
Apte, M. V., Park, S., Phillips, P. A., Santucci, N., Goldstein, D., Kumar, R. K., Ramm, G. A., Buchler, M., Friess, H., McCarroll, J. A., et al. (2004) · Pancreas · doi:10.1097/00006676-200410000-00002 · Cited by 591 · cited 1×
“and TGFβ1 mediates the dialogue between PSCs and PDAC cancer cells (Apte et al., 2004).”
BackgroundTGF-β and fibrosis in different organs — molecular pathway imprints
Pohlers, D., Brenmoehl, J., Löffler, I., Müller, C. K., Leipner, C., Schultze-Mosgau, S., Stallmach, A., Kinne, R. W., & Wolf, G. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.06.004 · Cited by 576
KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma
Morris, J. P., Wang, S. C., & Hebrok, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2899 · Cited by 567
TGF- : Duality of Function Between Tumor Prevention and Carcinogenesis
Principe, D. R., Doll, J. A., Bauer, J., Jung, B., Munshi, H. G., Bartholin, L., Pasche, B., Lee, C., & Grippo, P. J. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt369 · Cited by 523
Transforming growth factor-β in cancer and metastasis
Jakowlew, S. B. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9006-2 · Cited by 517
Park, J., Wrzesinski, S. H., Stern, E., Look, M., Criscione, J., Ragheb, R., Jay, S. M., Demento, S. L., Agawu, A., Licona Limon, P., et al. (2012) · Nature Materials · doi:10.1038/nmat3355 · Cited by 494
Morris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090353 · Cited by 487
Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq142 · Cited by 433
TGF-β signalling and its role in cancer progression and metastasis
Drabsch, Y., & ten Dijke, P. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9375-7 · Cited by 428
Roles of TGF-β family signaling in stem cell renewal and differentiation
Watabe, T., & Miyazono, K. (2009) · Cell Research · doi:10.1038/cr.2008.323 · Cited by 428
Uhl, M., Aulwurm, S., Wischhusen, J., Weiler, M., Ma, J. Y., Almirez, R., Mangadu, R., Liu, Y.-W., Platten, M., Herrlinger, U., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1013 · Cited by 414
Sánchez-Elsner, T., Botella, L. M., Velasco, B., Corbı́, A., Attisano, L., & Bernabéu, C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104536200 · Cited by 380
Beyond TGFβ: roles of other TGFβ superfamily members in cancer
Wakefield, L. M., & Hill, C. S. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3500 · Cited by 374
Nemunaitis, J., Dillman, R. O., Schwarzenberger, P. O., Senzer, N., Cunningham, C., Cutler, J., Tong, A., Kumar, P., Pappen, B., Hamilton, C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.5335 · Cited by 367
Biswas, S., Guix, M., Rinehart, C., Dugger, T. C., Chytil, A., Moses, H. L., Freeman, M. L., & Arteaga, C. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30740 · Cited by 346
TGF-β signaling in tissue fibrosis: Redox controls, target genes and therapeutic opportunities
Samarakoon, R., Overstreet, J. M., & Higgins, P. J. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2012.10.003 · Cited by 332
Coulouarn, C., Factor, V. M., & Thorgeirsson, S. S. (2008) · Hepatology · doi:10.1002/hep.22283 · Cited by 332
Mimeault, M., & Batra, S. K. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12004 · Cited by 330
Melisi, D., Ishiyama, S., Sclabas, G. M., Fleming, J. B., Xia, Q., Tortora, G., Abbruzzese, J. L., & Chiao, P. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0337 · Cited by 323
Smad4 signalling in T cells is required for suppression of gastrointestinal cancer
Kim, B.-G., Li, C., Qiao, W., Mamura, M., Kasperczak, B., Anver, M., Wolfraim, L., Hong, S., Mushinski, E., Potter, M., et al. (2006) · Nature · doi:10.1038/nature04846 · Cited by 322
Xu, Z., Wang, Y., Zhang, L., & Huang, L. (2014) · ACS Nano · doi:10.1021/nn500216y · Cited by 284
Van De Water, L., Varney, S., & Tomasek, J. J. (2013) · Advances in Wound Care · doi:10.1089/wound.2012.0393 · Cited by 251
Zhang, M., Kleber, S., Röhrich, M., Timke, C., Han, N., Tuettenberg, J., Martin-Villalba, A., Debus, J., Peschke, P., Wirkner, U., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1212 · Cited by 249
Transforming growth factor-β and the hallmarks of cancer
Tian, M., Neil, J. R., & Schiemann, W. P. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2010.10.015 · Cited by 244
Pancreatic Stellate Cells and Pancreatic Cancer Cells: An Unholy Alliance
Vonlaufen, A., Phillips, P. A., Xu, Z., Goldstein, D., Pirola, R. C., Wilson, J. S., & Apte, M. V. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1132 · Cited by 220
Targeting TGF-β signaling in cancer
Katz, L. H., Li, Y., Chen, J.-S., Muñoz, N. M., Majumdar, A., Chen, J., & Mishra, L. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.782287 · Cited by 212
Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression
Wendt, M. K., Tian, M., & Schiemann, W. P. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1199-1 · Cited by 210
Transforming Growth Factor-β in the Gastrointestinal and Hepatic Tumor Microenvironment
Achyut, B. R., & Yang, L. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.048 · Cited by 199
Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer
Senzer, N., Barve, M., Kuhn, J., Melnyk, A., Beitsch, P., Lazar, M., Lifshitz, S., Magee, M., Oh, J., Mill, S. W., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.269 · Cited by 198
Switching TGFβ from a tumor suppressor to a tumor promoter
Inman, G. J. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.12.004 · Cited by 197
Molecular Pathways: Targeting the TGF-β Pathway for Cancer Therapy
Smith, A. L., Robin, T. P., & Ford, H. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3224 · Cited by 193
Signaling Pathways Governing Tumor Angiogenesis
Sakurai, T., & Kudo, M. (2011) · Oncology · doi:10.1159/000333256 · Cited by 190
TGF-β family signaling in stem cells
Sakaki‐Yumoto, M., Katsuno, Y., & Derynck, R. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.08.008 · Cited by 186
Basics of TGF-ß and Pancreatic Cancer
Truty, M. J., & Urrutia, R. (2007) · Pancreatology · doi:10.1159/000108959 · Cited by 185
Mazzocca, A., Fransvea, E., Dituri, F., Lupo, L., Antonaci, S., & Giannelli, G. (2010) · Hepatology · doi:10.1002/hep.23285 · Cited by 176
Wilson, E. B., El-Jawhari, J. J., Neilson, A. L., Hall, G. D., Melcher, A. A., Meade, J. L., & Cook, G. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022842 · Cited by 174
Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas
Neuzillet, C., Gramont, A. D. E., Tijeras‐Raballand, A., de Mestier, L., Cros, J. F., Faivre, S. J., & Raymond, É. (2013) · Oncotarget · doi:10.18632/oncotarget.1569 · Cited by 172
Self-citationCopple, B. L. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02205.x · Cited by 164 · cited 1×
“For example, TGFβ cooperates with hypoxia to induce EMT and VEGF signaling through HIF-1α induction (Copple, 2010; Drabsch & ten Dijke, 2012; Mimeault & Batra, 2013).”
BackgroundTransforming Growth Factor-β and the Immune Response to Malignant Disease
Teicher, B. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1654 · Cited by 159
Stellate cells and the development of liver cancer: Therapeutic potential of targeting the stroma
Coulouarn, C., & Clément, B. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.02.003 · Cited by 149
Reversal of Tumor-induced Immunosuppression by TGF-β Inhibitors
Wojtowicz‐Praga, S. (2003) · Investigational New Drugs · doi:10.1023/a:1022951824806 · Cited by 146
Transforming growth factor‐beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer
Schlingensiepen, K., Jaschinski, F., Lang, S. A., Moser, C., Geissler, E. K., Schlitt, H. J., Kielmanowicz, M., & Schneider, A. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01917.x · Cited by 143
Nerve-cancer interactions in the stromal biology of pancreatic cancer
Demir, İ. E., Friess, H., & Ceyhan, G. O. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00097 · Cited by 139
Targeting transforming growth factor-β signaling in liver metastasis of colon cancer
Zhang, B., Halder, S. K., Zhang, S., & Datta, P. K. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.11.035 · Cited by 134
Gaspar, N. J., Li, L., Kapoun, A. M., Medicherla, S., Reddy, M., Li, G., O’Young, G., Quon, D. H., Henson, M., Damm, D. L., et al. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.029025 · Cited by 133
Mazzocca, A., Fransvea, E., Lavezzari, G., Antonaci, S., & Giannelli, G. (2009) · Hepatology · doi:10.1002/hep.23118 · Cited by 127
Pancreatic Cancer: The Role of Pancreatic Stellate Cells in Tumor Progression
Dunér, S., Lindman, J. L., Ansari, D., Gundewar, C., & Andersson, R. E. (2011) · Pancreatology · doi:10.1159/000320711 · Cited by 122
TGF-beta in neural stem cells and in tumors of the central nervous system
Aigner, L., & Bogdahn, U. (2007) · Cell and Tissue Research · doi:10.1007/s00441-007-0466-7 · Cited by 117
Targeting the Ras–ERK pathway in pancreatic adenocarcinoma
Neuzillet, C., Hammel, P. R., Tijeras‐Raballand, A., Couvelard, A., & Raymond, É. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9396-2 · Cited by 108
Self-citationDituri, F., Mazzocca, A., Peidrò, F. J., Papappicco, P., Fabregat, I., Santis, F. D., Paradiso, A., Sabbà, C., & Giannelli, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067109 · Cited by 103
Insights into the Transforming Growth Factor-β Signaling Pathway in Cutaneous Melanoma
Perrot, C. Y., Javelaud, D., & Mauviel, A. (2013) · Annals of Dermatology · doi:10.5021/ad.2013.25.2.135 · Cited by 101
Ito, N., Kawata, S., Tamura, S., Shirai, Y., Kiso, S., Tsushima, H., & Matsuzawa, Y. (1995) · Cancer Letters · doi:10.1016/0304-3835(95)90156-6 · Cited by 96
Inhibiting TGF-β signaling restores immune surveillance in the SMA-560 glioma model
Tran, T.-T., Uhl, M., Jing, Y., et al. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-010 · Cited by 96
Zhang, M., Herion, T., Timke, C., Han, N., Hauser, K., Weber, K. J., Peschke, P., Wirkner, U., Lahn, M., & Huber, P. E. (2011) · Neoplasia · doi:10.1593/neo.11258 · Cited by 94
Kim, S., Buchlis, G., Fridlender, Z. G., Sun, J., Kapoor, V., Cheng, G., Haas, A. R., Cheung, H. K., Zhang, X., Corbley, M. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1494 · Cited by 85
Tanaka, H. (2010) · Oncology Reports · doi:10.3892/or_00001028 · Cited by 83
Gil‐Guerrero, L., Dotor, J., Huibregtse, I. L., Casares, N., López-Vázquez, A. B., Rudilla, F., Riezu‐Boj, J. I., López‐Sagaseta, J., Hermida, J., van Deventer, S. J. H., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.126 · Cited by 81
Dzieran, J., Fabian, J., Feng, T., Coulouarn, C., Ilkavets, I., Kyselova, A., Breuhahn, K., Dooley, S., & Meindl‐Beinker, N. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072252 · Cited by 81
Díaz‐Valdés, N., Basagoiti, M., Dotor, J., Aranda, F., Monreal‐Santesteban, I., Riezu‐Boj, J. I., Borrás‐Cuesta, F., Sarobe, P., & Feijoó, E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2698 · Cited by 71
Transforming growth factor-beta and its implication in the malignancy of gliomas
Roy, L.-O., Poirier, M.-B., & Fortin, D. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0308-y · Cited by 70
Garrison, K., Hahn, T., Lee, W., Ling, L. E., Weinberg, A. D., & Akporiaye, E. T. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1119-y · Cited by 70
Peptide inhibitors of transforming growth factor‐β enhance the efficacy of antitumor immunotherapy
Llópiz, D., Dotor, J., Casares, N., Bezunartea, J., Díaz‐Valdés, N., Ruiz, M., Aranda, F., Berraondo, P., Prìeto, J., Lasarte, J. J., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24656 · Cited by 66
TGFβ and cancer metastasis: an inflammation link
Yang, L. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9226-3 · Cited by 65
Phase I Trial of TGF-β2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine
Olivares, J., Kumar, P., Yu, Y., Maples, P. B., Senzer, N. N., Bedell, C., Barve, M. A., Tong, A., Pappen, B. O., Kuhn, J. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2195 · Cited by 64
Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
Medicherla, S., Li, L., Jing, Y., Kapoun, A. M., Gaspar, N. J., Liu, Y.-W., Mangadu, R., O’Young, G., Protter, A. A., Schreiner, G. F., et al. (2007) · PubMed · Cited by 61
The Smads: transcriptional regulation and mouse models
Datto, M., & Wang, X.-F. (2000) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(99)00027-1 · Cited by 57
Shima, K., Morikawa, T., Yamauchi, M., Kuchiba, A., Imamura, Y., Liao, X., Meyerhardt, J. A., Fuchs, C. S., & Ogino, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025062 · Cited by 57
Ogino, S., Kawasaki, T., Ogawa, A., Kirkner, G. J., Loda, M. F., & Fuchs, C. S. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.10.005 · Cited by 56
Necchi, A., Giannatempo, P., Mariani, L., Farè, E., Raggi, D., Pennati, M., Zaffaroni, N., Crippa, F., Marchianò, A. V., Nicolai, N., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0074-9 · Cited by 55
Haas, S., Haas, S. R. L., Fitzner, B., Haas, S. R. L., Fitzner, B., Jaster, R., Wiercinska, E., Gaitantzi, H., Jesenowski, R., Löhr, M. J., et al. (2009) · Growth Factors · doi:10.1080/08977190903132273 · Cited by 54
Yang, X., Chen, G.-L., Yu, S., Xu, C. S., Xin, Y.-H., Li, T., Shi, Y., Ai, G., Duan, J., Qian, C., et al. (2012) · International Immunopharmacology · doi:10.1016/j.intimp.2012.12.002 · Cited by 53
COHN, A., LAHN, M. M., WILLIAMS, K. E., CLEVERLY, A. L., PITOU, C., KADAM, S. K., FARMEN, M. W., DESAIAH, D., RAJU, R., CONKLING, P., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2679 · Cited by 43
Hatziieremia, S., McCall, P., Willder, J. M., Orange, C., Seywright, M. M., Underwood, M. A., & Edwards, J. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-1 · Cited by 36
Oyanagi, J., Kojima, N., Sato, H., Higashi, S., Kikuchi, K., Sakai, K., Matsumoto, K., & Miyazaki, K. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.04.009 · Cited by 35
Akbari, A., Amanpour, S., Muhammadnejad, S., Ghahremani, M. H., Ghaffari, S. H., Dehpour, A. R., Mobini, G. R., Shidfar, F., Abastabar, M., Khoshzaban, A., et al. (2014) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/2008-2231-22-47 · Cited by 33 · cited 1×
“Similarly, reduced vessel density after treatment with TGFβ pathway inhibitor was reported in colorectal cancer with SD-208 (Akbari et al., 2014), and in glioblastoma models using LY2109761 (Zhang et al.”
Transforming growth factor-β gene silencing using adenovirus expressing TGF-β1 or TGF-β2 shRNA
Oh, S., Kim, E., Kang, D., Kim, M., Kim, J.-H., & Song, J. J. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2012.90 · Cited by 18
Goff, L. W., de Braud, F., Cohen, R. B., Berlin, J. D., Noberasco, C., Borghaei, H., Wang, E., Lowe, D., Levin, W. J., & Gallo‐Stampino, C. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3034 · Cited by 14
Self-citation
Cited by
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539
Concepts of extracellular matrix remodelling in tumour progression and metastasis
Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J., & Werb, Z. (2020) · Nature Communications · doi:10.1038/s41467-020-18794-x · Cited by 2,296
The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144
Nedeljković, M., & Damjanović, A. (2019) · Cells · doi:10.3390/cells8090957 · Cited by 870
Metadata
- Authors
- Neuzillet, C., Tijeras-Raballand, A., Cohen, R., Cros, J., Faivre, S., Raymond, E., & de Gramont, A.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 147
- Pages
- 22-31
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2000315116
- Cited by
- 611
- References
- 89
- FWCI
- 12.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.